Evaluation of safety and efficiency of treatment with autologous cytokine-induced killer cell for hepatocellular carcinoma
- VernacularTitle:自体CIK细胞治疗肝癌的安全性和有效性评价
- Author:
Ming SHI
;
Fusheng WANG
;
Bing ZHANG
- Publication Type:Journal Article
- Keywords:
cytokine-induced killer cells;
hepatocellular carcinoma;
safety;
efficiency
- From:
Medical Journal of Chinese People's Liberation Army
1981;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficiency of the treatment with autologous cytokine-induced killer (CIK) cell in patients with hepatocellular carcinoma (HCC). Methods Peripheral blood mononuclear cells (PBMC) were isolated from blood from patients with HCC, then augmented by priming with interferon-gamma (IFN-?) followed by monoclonal antibody (mAb) against CD3 and interleukin-2 (IL-2). The autologous CIK cells thus obtained were infused back to individual patients. Altogether 30 patients undertook such treatment. The changes in subsets of lymphocytes and dendritic cells (DC1, DC2) in peripheral blood were assessed by using flow cytometry. Results The percentages of CD3 +, CD3 + CD8 + , CD3 + CD56 + , and CD25 + were increased significantly, and the proportions of DC1 and DC2 subsets were also increased after autologous CIK cells transfusion. Most (23 of 30) patients developed a fever 1-2 hours after CIK cells transfusion and the body temperature ranged from 37℃ to 40℃, lasting for 2-8 hours. Most (20 of 23) febrile patients recovered without any treatment, antipyretic medicine was given to 3 patients to allay the fever. The HCC symptoms were markedly relieved in most patients. No major side effects were found. Conclusion Our observation indicates that the treatment with autologous CIK cells for HCC patients is safe and efficacious.
